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OBJECTIVES To assess the effects of nicotinic acid (NA), gemfibrozil and combination therapy on the lipid
profile of patients with clinical atherosclerotic disease and isolated hypoalphalipoproteinemia.
BACKGROUND Isolated hypoalphalipoproteinemia (low high density lipoprotein cholesterol [HDL-C] alone)
accounts for a significant percentage of patients with premature atherosclerosis. However, it
remains unclear whether currently available pharmacotherapy has the ability to favorably affect
the lipid profile and therefore potentially reduce clinical events.
METHODS Twenty-three patients with clinically well-defined atherosclerosis and isolated hypoalphali-
poproteinemia were prospectively randomized to receive gemfibrozil, NA or combination
therapy in an open-label, crossover design trial to assess the effects on serum lipids. Lipid
profiles and other relevant laboratory variables were monitored while the patients were on and
off pharmacologic lipid-modulating therapy.
RESULTS In those 14 patients able to tolerate all forms of pharmacotherapy, HDL-C of 0.89 6 0.17
mmol/liter (34.5 6 6.5 mg/dl) increased by 15%, to 1.02 6 0.18 mmol/liter (39.7 6 7.1
mg/dl), while taking gemfibrozil (1200 mg/day); by 35%, to 1.20 6 0.21 mmol/liter (46.5 6
8.1 mg/dl), while taking NA (mean dose 2,250 mg/day); and by 45%, to 1.29 6 0.19
mmol/liter (50.0 6 7.5 mg/dl), while taking combination therapy of gemfibrozil plus NA
(p , 0.001 for all interventions as compared with baseline/washout; p , 0.005 NA vs.
gemfibrozil; p , 0.001 combination therapy vs. gemfibrozil alone; p 5 0.088 combination
therapy vs. NA alone). Statistically significant favorable alterations were also observed with
low density lipoprotein cholesterol (LDL-C), LDL-C/HDL-C, non-HDL-C/HDL-C,
apolipoprotein (Apo) B and Apo B/Apo A1.
CONCLUSIONS In the majority of patients with clinical atherosclerotic disease and isolated hypoalphalipopro-
teinemia, pharmacologic therapy to raise HDL-C is not only feasible but is also effective with
currently available agents, particularly when used in combination. (J Am Coll Cardiol 2000;
35:640–6) © 2000 by the American College of Cardiology
In the decade since the first published results of the
Honolulu (1), Framingham (2) and Tromso (3) studies, the
independent, strong, inverse relation between levels of high
density lipoprotein cholesterol (HDL-C) and coronary
artery disease (CAD) has been confirmed, with a few
exceptions according to epidemiologic studies in several
countries (4–11). Although low levels of HDL-C are often
associated with elevated levels of plasma triglycerides or low
density lipoprotein cholesterol (LDL-C), or both (12–14),
primary hypoalphalipoproteinemia in non-obese, nonsmok-
ing and regularly exercising individuals has been well doc-
umented (15,16), may be familial (17) and is associated with
the development of premature clinical CAD (17,18). In-
deed, of those patients undergoing diagnostic coronary
arteriography, between 4% and 19% have been shown to
have hypoalphalipoproteinemia, as defined earlier, as their
sole lipid abnormality (16–19). Although the Helsinki heart
study showed a decrease in CAD risk that appeared to be
associated with a pharmacologically induced increase in
HDL-C, the results were limited to patients with moderate
to high levels of LDL and very low density lipoprotein
cholesterol (VLDL-C) combined. No clinical end point
trial has yet been published that specifically targets patients
with isolated low levels of HDL-C for intervention. A
seemingly necessary prerequisite for cardiac event reduction
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in this patient group, however, would seem to be a signif-
icant increase in HDL-C by the intervention under study.
The present report was a randomized, controlled, open-
label, crossover trial of gemfibrozil, nicotinic acid (NA) and
combination gemfibrozil plus a maximally tolerated dose of
NA in patients with primary hypoalphalipoproteinemia, all
of whom had documented atherosclerotic vascular disease,
to assess the effect of these agents on the lipid profile.
Secondarily, safety and tolerability of individual therapies in
this small group of patients were also examined.
METHODS
Patient group. Twenty-six adult patients with atheroscle-
rotic vascular disease who had already been stabilized by
step 2 of the National Cholesterol Education Program
(NCEP) diet and had total cholesterol (TC) ,220 mg/dl,
LDL-C ,160 mg/dl, HDL-C ,40 mg/dl and triglycerides
,200 mg/dl on two consecutive lipid profiles within two
months of study entry were deemed eligible for study. These
values were chosen to define isolated hypoalphalipopro-
teinemia based on previously published studies (20,21).
During screening, patients were excluded if they had dia-
betes mellitus, gouty arthritis, abnormal liver function,
thyroid disease, psychiatric illness, drug or alcohol abuse or
if they were undergoing treatment with lipid-lowering
agents, anticonvulsant agents or corticosteroids.
Twenty-three patients (22 men and 1 woman, 41 to 80
years old [mean 61]), many of whom were enrolled in a
maintenance exercise cardiac rehabilitation program, freely
agreed to participate and were randomly assigned to study
medications. Twenty-two patients had a history of CAD
(17 with S/P remote myocardial infarction, three with S/P
remote coronary artery bypass graft surgery and two with
chronic stable angina) and one had proven peripheral
vascular disease. Body mass index was 26 6 3 kg/m2. All
patients either were nonsmokers or had quit smoking over
three months before study enrollment. Patients taking a
variety of cardiovascular drugs for control of angina, hyper-
tension or congestive heart failure were allowed to partici-
pate only if they maintained the same dosage regimen
throughout the entire study, with two exceptions: One
patient discontinued dyazide after the initial dietary run-in
phase before drug randomization and another had furo-
semide added for the treatment of peripheral edema while
taking NA therapy.
Treatment protocol. Patients were initially screened by
laboratory assessment and physical examination. All pa-
tients had previously been placed on an isocaloric saturated
fat/cholesterol-restricted NCEP step 2 maintenance diet
(22) by a registered dietician for a minimum of 12 weeks.
Compliance with the diet throughout the entire study
period was established by taking once a month three-day
dietary histories, the data from which were entered by the
dietician into a standard software computer analysis pro-
gram (Nutritionist III, N-Squared Computing, Silverton,
Oregon). Patients were seen in the office at least every 12
weeks, at which time they were interviewed and recounseled
regarding dietary and drug adherence to the program,
maintenance of body weight and level of exercise habit.
Patients who met the inclusion criteria were randomized
to receive either open-label drug with gemfibrozil, 600 mg
orally twice a day, or immediate-release crystalline NA, 100
to 250 mg orally three times a day, with meals. The first
patient was randomized to gemfibrozil, the second to NA
and so forth. For gemfibrozil, 600 mg twice a day is both the
recommended initial and maximal dose. For NA, the dose
was gradually increased, initially to 1,500 mg/day and
subsequently to the maximally tolerated dose, not to exceed
3,000 mg/day. On completion of three months of maximal
dosing with either agent, or sooner if intolerant to therapy,
the patient was subsequently crossed over to the other
treatment arm. If the patient was able to tolerate both
gemfibrozil and NA individually, combination therapy with
gemfibrozil, 600 mg orally twice a day, and the previous
maximally tolerated dose of NA was administered for an
additional three-month period. After completion of the
active drug portion of the study, all pharmacologic lipid-
lowering therapy was discontinued, and three months later
a pair of control sera was obtained one week apart for lipid
analysis. These values were averaged with the pretreatment
eligibility lipid profiles to derive the baseline values (Table
1). During the run-in phase and at the end of each drug
treatment phase, blood for routine hematologic liver func-
tion, creatine kinase and a minimum of two samples at
weekly intervals for lipid and apolipoprotein (Apo) levels
were drawn and analyzed.
Lipid analyses. Lipid profiles, Apo B and Apo A1 con-
centrations were measured at Roche Laboratories (Nutley,
New Jersey). Total serum cholesterol was measured enzy-
matically with an analyzer (Olympus-AU 5000, Melville,
New York) with a coefficient of variation of 1.6% (data
provided by Roche Laboratories). The HDL-C levels were
determined by fractionating with manganese and dextran
followed by centrifugation. The HDL containing superna-
Abbreviations and Acronyms
Apo A1 5 apolipoprotein A1
Apo B 5 apolipoprotein B
CAD 5 coronary artery disease
HDL-C 5 high density lipoprotein cholesterol
LDL-C 5 low density lipoprotein cholesterol
NA 5 nicotinic acid
NCEP 5 National Cholesterol Education Program
TC 5 total cholesterol
VA-HIT 5 High-density-lipoprotein Intervention Trial
of the Department of Veterans Affairs
VLDL-C 5 very low density lipoprotein cholesterol
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tant was assayed for cholesterol by an enzymatic chromo-
phobic technique (American Monitor, KDA Analyzer) with
a coefficient of variation of 4.1% (data provided by Roche
Laboratories). Triglyceride levels were measured enzymati-
cally with an Olympus-AU 5000 analyzer with a coefficient
of variation of 2.4% (data provided by Roche Laboratories).
The VLDL-C levels were estimated by dividing the trig-
lycerides by 5, as described by Friedewald et al. (23).
Non–HDL-C was calculated by subtracting the measured
HDL-C from the measured TC. LDL-C was calculated by
subtracting VLDL-C and HDL-C from TC. Apolipopro-
teins A1 and B were measured in sera using immunoneph-
elometry with a Cobas Bio centrifugal analyzer and anti-
bodies against human Apo A1 and Apo B provided by
Reagents Applications, Inc. (San Diego, California).
Statistical analysis. Single-factor repeated measures anal-
ysis of variance (ANOVA) (24) was performed to assess
differences between the four study phases (dietary alone
[baseline plus follow-up washout], diet plus gemfibrozil,
diet plus NA and diet plus gemfibrozil plus NA). Lipid
values after the dietary run-in phase and after drug washout
were combined and presented as baseline to attempt to
minimize regression to the mean (25). Statistical compari-
sons with baseline were performed in 21, 17 and 14 patients
who were able to tolerate gemfibrozil, some dose of NA and
combination gemfibrozil plus NA. When the F statistic by
ANOVA was significant (alpha 0.05), multiple comparisons
were made using the paired two-tailed t test with the
Bonferroni correction to adjust for multiplicity of testing.
Six comparisons were made, and significance was defined at
an alpha value of 0.05/6, or 0.0083, or lower.
RESULTS
The baseline characteristics of the patients before random-
ization are shown in Table 2. Throughout the course of the
study, body weight change, by design, was minimal (mean
20.8 lb [range 29.0 to 19.3]), which represented only
0.5% (range 26.5% to 4.1%) of baseline. Patients remained
compliant with the low cholesterol–low fat diet (average
cholesterol 167 6 27 mg/day; 22.0 6 5.3 calories derived
from fat with a polyunsaturated, saturated, monosaturated
fat ratio of 1.0:1.4:1.4) throughout the entire study period.
The effects of gemfibrozil or NA individually on the lipid
profile in the 21 and 17 patients, respectively, who tolerated
these agents as monotherapy did not differ from the lipid
profile of the 14 patients who were able to tolerate combi-
nation therapy. As such, only data from the final group of
patients (n 5 14) who were able to tolerate gemfibrozil, low
or high dose NA and combination gemfibrozil plus NA for
the entire study period are presented (Table 1). The values
displayed for NA are derived from the highest tolerated
dose in a given patient.
On gemfibrozil monotherapy, two patients discontinued
active drug therapy—one because of nausea and the other
because of asthenia—before follow-up lipid studies were
performed. Gemfibrozil decreased triglycerides by 31% and
LDL-C by 10% and increased HDL-C by 15% in compar-
ison with baseline. A significant inverse correlation (p 5
Table 1. Comparison of Responses to Gemfibrozil, Nicotinic Acid and Combination Pharmacotherapy in Patients (n 5 14) With
Isolated Hypoalphalipoproteinemia
Baseline Gemfibrozil Nicotinic Acid Combined Therapy
Level in mmol/liter (mg/dl)
Total cholesterol 4.87 6 0.69 (189 6 27) 4.49 6 0.70 (174 6 27)* 4.33 6 0.74 (168 6 29)* 3.91 6 0.76 (152 6 29)*†‡
LDL-C 3.40 6 0.60 (132 6 23) 3.06 6 0.64 (119 6 25)* 2.67 6 0.64 (104 6 25)*† 2.33 6 0.72 (91 6 28)*†‡
HDL-C 0.89 6 0.17 (35 6 7) 1.02 6 0.18 (40 6 7)* 1.20 6 0.21 (47 6 8)*† 1.29 6 0.19 (50 6 8)*†
Triglycerides 1.28 6 0.43 (113 6 38) 0.87 6 0.45 (78 6 40)* 1.02 6 0.58 (91 6 52) 0.65 6 0.22 (58 6 20)*
Apo B 2.31 6 0.51 (90 6 20) 1.94 6 0.42 (75 6 16)† 1.69 6 0.51 (66 6 20)*† 1.51 6 0.54 (59 6 21)*†
Apo A1 2.97 6 0.44 (115 6 17) 3.14 6 0.36 (122 6 14) 3.38 6 0.36 (131 6 14) 3.58 6 0.56 (139 6 22)*†
Ratio
LDL-C/HDL-C 3.9 6 0.9 3.1 6 0.9* 2.3 6 0.9*† 1.9 6 0.7*†‡
Non–HDL-C/HDL-C 4.6 6 1.2 3.5 6 1.1* 2.8 6 1.1* 2.1 6 0.8*†‡
Apo B/Apo A1 0.82 6 0.21 0.63 6 0.11 0.53 6 0.16* 0.43 6 0.13*†
*Significantly different from baseline. †Significantly different from gemfibrozil. ‡Significantly different from nicotinic acid. Data are presented as the mean value 6 SD.
Apo 5 apolipoprotein; HDL-C 5 high density lipoprotein cholesterol; LDL-C 5 low density lipoprotein cholesterol; TC 5 total cholesterol.
Table 2. Baseline Characteristics of Patients (n 5 23) With
Isolated Low High Density Lipoprotein Cholesterol
Before Randomization
Age (yrs) 60.9 6 11.5
Gender (M/F) 22/1
Diagnosis 22 CAD, 1 PVD
Weight (lb) 177.9 6 28.1
BMI (kg/m2) 26.0 6 3.0
Level in mmol/liter (mg/dl)
Total cholesterol 4.90 6 0.62 (190.4 6 24.2)
LDL-C 3.38 6 0.51 (131.3 6 19.6)
HDL-C 0.86 6 0.14 (33.3 6 5.6)
Triglycerides 1.46 6 0.53 (129.6 6 47.8)
Apo A1 2.93 6 0.35 (113.5 6 13.7)
Apo B 2.36 6 0.47 (91.4 6 18.1)
Data are presented as the mean value 6 SD or number of patients.
BMI 5 body mass index; CAD 5 coronary artery disease; PVD 5 peripheral
vascular disease; other abbreviations as in Table 1.
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0.014 for the group correlation coefficient) was noted
between the decrease in triglycerides and the increase in
HDL-C (r 5 20.63). The LDL-C/HDL-C and non–
HDL-C/HDL-C ratios were significantly decreased by
21% and 24%, respectively.
Twenty-three patients were initially treated with
immediate-release crystalline niacin, and six patients expe-
riencing severe flushing were subsequently treated with
slow-release NA. On low dose NA (mean dose
1,400 mg/day [range 1,000 to 1,500]), six patients experi-
enced one or more side effects necessitating withdrawal
from therapy. Two subjects had an attack of gout, two had
urticaria, two had a pruritic macular rash, one had nausea
and one had asymptomatic transaminasemia. In comparison
with baseline, low dose NA decreased LDL-C by 14% and
increased HDL-C by 26%. The LDL-C/HDL-C and
non–HDL-C/HDL-C ratios were both decreased by 29%,
consistent with a lack of triglyceride lowering on low dose
NA. The Apo B/Apo A1 ratio decreased by 13%.
Seventeen patients who tolerated low dose NA were
advanced to high dose NA (mean dose 2,250 mg/day [range
2,000 to 3,000]). Fourteen patients were treated with
immediate-release crystalline niacin and three with slow-
release NA. On high dose NA, four patients experienced
one or more side effects necessitating withdrawal from
therapy. Three subjects had severe nausea, one had dizzi-
ness, one had myalgias and two had asymptomatic
transaminasemia. In comparison with baseline, high dose
NA significantly decreased LDL-C and Apo B by 22% and
27%, respectively, and increased HDL-C by 35%. No
significant correlation (p 5 0.126 for the group correlation
coefficient) was noted between the 20% decrease in triglyc-
erides and the increase in HDL-C (r 5 20.43). The
LDL-C/HDL-C, non–HDL-C/HDL-C and Apo B/Apo
A1 ratios were significantly decreased by 41%, 39% and
35%, respectively.
Fifteen patients underwent combined therapy with gem-
fibrozil and the highest dose of NA, which previously had
been tolerated as monotherapy. Ten patients were treated
with immediate-release crystalline niacin and five with
slow-release NA. On combination lipid-lowering therapy,
one patient who had previously experienced only mild
nausea on gemfibrozil now had severe nausea, which re-
solved on discontinuation of gemfibrozil. No patient had
myalgias or myositis. Combination therapy in 14 patients
significantly decreased LDL-C by 31%, 24% and 13% in
comparison with baseline, gemfibrozil and the previous
maximally tolerated dose of NA, respectively. Apo B was
significantly decreased by 35% and 22% in comparison with
baseline and gemfibrozil monotherapy, respectively.
HDL-C and Apo A1 were significantly increased by 45%
and 21%, respectively, and by 26% and 14% in comparison
with baseline and gemfibrozil monotherapy, respectively.
LDL-C/HDL-C was significantly reduced by 51%, 39%
and 17% in comparison with baseline, gemfibrozil and the
previous maximally tolerated dose of NA, respectively.
Non–HDL-C/HDL-C was significantly reduced by 54%,
40% and 25% in comparison with baseline, gemfibrozil and
the previous maximally tolerated dose of NA, respectively.
Apo B/Apo A1 was significantly decreased by 48% and 32%
in comparison with baseline and gemfibrozil monotherapy,
respectively.
DISCUSSION
It is clear from multiple angiographic (26–30) as well as
clinical outcome trials (31–34) that LDL-C is a potent risk
factor for the development of atherosclerotic CAD and that
pharmacologic therapy designed to lower LDL-C in certain
high risk patient groups results in slower progression of
atherosclerotic disease as well as a reduction in both fatal
and nonfatal myocardial infarctions. That such therapy is
capable of reducing but not eliminating further progression
of the atherosclerotic process is consistent with the known
multifactorial nature of this disease and the presence of
other significant dyslipidemias in this patient group
(18,19,35,36). Paramount among these dyslipidemias are
disorders associated with a low HDL-C, a lipoprotein
closely associated with reverse cholesterol transport (37,38)
and a known independent inverse risk factor for the devel-
opment of atherosclerotic heart disease (39). Until recently,
however, evidence to suggest that drug therapy which can
increase HDL-C may be associated with decreased cardiac
morbid events was quite limited (40,41) and confined to
those patients with significant mixed hyperlipidemia (i.e.,
increased LDL-C and triglycerides) in whom there had
been a concomitant reduction of LDL-C and triglycerides
(42,43). With the recent publication of the large secondary
prevention High-density lipoprotein cholesterol Interven-
tion Trial of the Department of Veterans Affairs (VA-HIT)
(44), however, it is now clear that a meaningful reduction in
the risk of future major cardiovascular events is possible in
patients with hypoalphalipoproteinemia, perhaps by raising
HDL-C without lowering LDL-C.
In the current study, patient acceptance of gemfibrozil
was quite high (91% [21 of 23 patients]) and was associated
with a modest increase in HDL-C and a major decrease in
triglycerides. Although the increase in HDL-C that we
found somewhat exceeds that reported by some investiga-
tors (44–46), it is similar to that described by others (47)
and also to that associated with the use of reductase
inhibitors in comparable patient groups (46,48). In the
current series of normotriglyceridemic subjects, the rise in
HDL-C with the use of gemfibrozil was inversely related to
the fall in triglycerides, as previously reported in patients
with hypertriglyceridemia (45,49,50). Like previously re-
ported series of patients with isolated hypoalphalipopro-
teinemia (45,46), the increase in HDL-C was not associated
with any increase in Apo A1. This is in contrast to the
increase in Apo A1 seen in patients with phenotypic type IV
hyperlipoproteinemia treated with gemfibrozil (50,51).
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In the current study, 6 (26%) of 23 patients and an
additional 4 (17%) of 23 patients were unable to tolerate at
least three months of low dose or high dose NA therapy,
respectively. This is similar to the 36% to 40% rate of
intolerance reported in other prospective clinical trials in
which crystalline NA was used (21,52). As reported previ-
ously (21,53), most of the increase in HDL-C and Apo A1
can be accomplished by relatively low dose NA therapy. In
the current study, high dose NA (mean 2,250 mg/day) was
associated with a 35% and 13% increase in HDL-C and
Apo A1, respectively—values in good agreement with those
previously reported in patients with isolated hypoalphali-
poproteinemia treated similarly (21,52). In the current
study, unlike gemfibrozil, there was no clear relation be-
tween the amount of HDL-C increase and triglyerides
decrease in patients treated with NA. A similar finding was
reported in two previous series employing sustained-release
NA preparations in similar patient groups (20,53). Use of
high dose NA in the current study was associated with a
22% and 27% reduction in LDL-C and Apo B, respective-
ly—with these decrements following a more linear dose
response. These results are again consistent with the 14% to
18% and 21% to 32% reduction in LDL-C and Apo B,
respectively, previously reported in somewhat similar pa-
tients (21,52).
To our knowledge, this is the first study, in the same
group of patients with isolated hypoalphalipoproteinemia,
to address the question of combination gemfibrozil and NA
therapy with regard to the effects on blood lipids. With
combination therapy, LDL-C, Apo B and triglycerides
were reduced by 31%, 35% and 49%, respectively, with the
LDL-C reduction being greater than that while using
gemfibrozil or NA alone. With combination therapy,
HDL-C was increased by 45% over baseline and signifi-
cantly further when compared with gemfibrozil alone.
LDL-C/HDL-C, non–HDL-C/HDL-C and Apo B/Apo
A1 were reduced by 51%, 54% and 48%, respectively—each
of these reductions being greater than that while using
gemfibrozil or NA alone. Although the mechanism of
action of gemfibrozil to improve clinical outcomes in pa-
tients with hypoalphalipoproteinemia has not been proven
to be related to the increase in HDL-C (44), it is intriguing
to speculate on the potential dramatic reduction in cardiac
morbid events that may be achieved with combination
gemfibrozil and NA therapy, on the basis of the clearly
superior lipid profile with which the combination is associ-
ated. Although myositis and rhabdomyolysis were not
observed in this small series, caution must be exercised when
using this combination of agents, individualizing therapy
where potential benefit may outweigh the risks of treatment
(54).
By enhancing transcription of lipoprotein lipase, gemfi-
brozil appears to increase the catabolism of triglyceride-rich
lipoproteins, resulting in an increased transfer of surface
constituents to nascent HDL. In contrast to patients with
type IV hyperlipoproteinemia, in whom there appears to be
increased Apo A1 synthesis, in patients with isolated hy-
poalphalipoproteinemia, serum Apo A1 levels remain un-
changed, suggesting either a lack of anabolic effect or a
balanced increase in Apo A1 catabolism. The reduction in
LDL-C and Apo B reported here with NA therapy is
consistent with a decrease in VLDL particle synthesis (55).
In the current series of patients, the increase in HDL-C and
Apo A1 with NA therapy may occur largely by triglyceride-
independent mechanisms. The lack of correlation between
HDL-C increase and triglycerides decrease with NA ther-
apy, as well as the greater increase in HDL-C with NA as
compared with gemfibrozil therapy, despite the greater
decrease in triglycerides with use of gemfibrozil, is consis-
tent with this hypothesis. Measured lipid values suggest an
additive effect of these two agents in patients with isolated
hypoalphalipoproteinemia, consistent with their different
postulated mechanisms of action.
Because ;40% of patients could not tolerate one or both
of the pharmacologic agents used, data are presented using
an “on-treatment” as opposed to “intention-to-treat” anal-
ysis. To perform the latter would merely serve to dilute the
results and create the false impression that drug therapy,
even when effectively delivered, is of no value for patients
with isolated hypoalphalipoproteinemia.
Study limitations. The number of patients studied, al-
though relatively small, is consistent with those in previously
reported crossover trials of pharmacologic lipid-lowering
agents and is adequately powered by using appropriate
statistical methods to disprove multiple null hypotheses.
Although there was no true placebo group, it was hoped
that this effect would be minimized somewhat by the
crossover design of the trial. The study was nonblinded and
lacked objective measures to assess drug compliance. How-
ever, the frequent doctor–patient encounters during follow-
up, as well as the excellent agreement between baseline and
final washout lipid profiles and their significant differences
from those values obtained during treatment, suggest that
reasonable drug compliance was achieved in most cases.
Conclusions. A large body of epidemiologic data suggests
that low levels of HDL-C are strongly associated with an
increased risk of CAD. Results from the VA-HIT mega-
trial suggest that pharmacotherapy designed specifically to
raise HDL-C in a group of patients with CAD and
hypoalphalipoproteinemia and an otherwise unremarkable
lipid profile can result in a significant decrease in subsequent
morbid events from ischemic heart disease. Enrollment of
patients in the randomized, double-blind, placebo-
controlled Bezafibrate Infarction Prevention (BIP) (56)
secondary prevention trial has been completed and results
are pending.
The current study suggests that combination gemfibrozil
and NA therapy in patients with isolated hypoalphalipopro-
teinemia can result in dramatic improvement of the lipid
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profile—superior to that of either agent alone—in the
majority of patients in whom drug treatment can be toler-
ated. Although some investigators have advocated such
therapy (54,57), others have recommended treatment with
reductase inhibitors to lower the already relatively “normal”
LDL-C in these individuals, and thereby presumably de-
crease further the risk of atherosclerotic disease progression
(46,48,58). To do so, however, may be akin to drilling a hole
in the floor to drain water from a leak in the ceiling. Fixing
the ceiling, if it could be accomplished safely, would seem a
more logical approach.
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